GSK-licensed antibiotic meets goal in late-stage study
The British drugmaker may have succeeded in reviving an oral antibiotic previously rejected by the FDA when it was under development by Spero.
The British drugmaker may have succeeded in reviving an oral antibiotic previously rejected by the FDA when it was under development by Spero.
